Jiangsu Kanion Pharmaceutical Co.,ltd is a large scale Chinese medicine industrial enterprise dedicated to the R&D, Production and sales of modern Chinese medicine,It’s a national key high-tech enterprise, a national technological innovation demonstration enterprise, a national intellectual property demonstration enterprise and a domestic A-share listed company, China’s Top 100 pharmaceutical Companies (No.29), Ranked first in the list of “R&D strength of Chinese Medicine” for many consecutive years.
Look forward to the future, Kanion will continue to shoulder the mission of revitalizing Sinopharm, inheriting the essence, keeping integrity and innovative, stable quality safe and reliable, clinically recognized high-quality Chinese medicine, which will benefit the people’s health, and write a new chapter in the development of high quality Chinese medicine.
• Xiao wei, Doctor of Chinese Medicine, researcher, doctoral advisor, chairman and general manager of Jiangsu Kanion Pharmaceutical Co., Ltd., deputy to the 11th, 12th and 13th National People’s Congress, current director of National Key Laboratory for New Technologies in TCM Manufacturing Process, director of National and Local Joint Engineering Research Center for Intelligent Manufacturing of Chinese Patent Medicine, executive member of Chinese Pharmacopoeia Commission, vice chairman of China Association of Chinese Medicine, and managing director of Chinese Association of the Integration of Traditional and Western Medicine.
• He has concentrated on the studies in the new Chinese medicine innovation and manufacturing engineering technology field for more than 30 years and has made significant achievements and contributions to the technological innovation of TCM industry in China. As the “973” chief scientist, he has undertaken 13 projects including major new medicine innovation and manufacturing projects; as the first inventor, he has obtained 206 invention patents, including 31 international patents; as the first/corresponding author, he has published 258 articles, including 57 SCI; as the chief editor, he has written two books; he took charge of developing 9 standards in Chinese Pharmacopoeia. He won 1 second prize of National Technological Innovation (ranking first), 2 second prizes of National Scientific and Technological Progress Award (ranking first and second), 7 first prizes of Provincial and Ministerial Scientific and Technological Progress Award (all ranking first), Science and Technology Award of the Ho Leung Ho Lee Foundation, National Top Innovation Award, National Labor Medal, National Outstanding Scientific and Technological Worker, Chinese Pharmaceutical Development Award, and Outstanding Contribution Award of Jiangsu Manufacturing.
